End-of-day quote
Korea S.E.
03:30:00 20/05/2024 am IST
|
5-day change
|
1st Jan Change
|
8,910
KRW
|
-2.73%
|
|
-2.41%
|
-24.75%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
60,418
|
59,607
|
2,02,289
|
1,43,139
|
1,33,362
|
1,51,047
|
Enterprise Value (EV)
1 |
77,516
|
73,437
|
2,15,250
|
1,44,023
|
1,40,150
|
1,71,482
|
P/E ratio
|
-2.03
x
|
22.9
x
|
118
x
|
189
x
|
74
x
|
47.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.81
x
|
1.48
x
|
5
x
|
3.21
x
|
2.09
x
|
1.64
x
|
EV / Revenue
|
2.32
x
|
1.83
x
|
5.32
x
|
3.23
x
|
2.19
x
|
1.86
x
|
EV / EBITDA
|
90.3
x
|
11.6
x
|
31.7
x
|
20.3
x
|
14.5
x
|
14.3
x
|
EV / FCF
|
1,166
x
|
-187
x
|
-13.7
x
|
-34.6
x
|
-61.5
x
|
-14.9
x
|
FCF Yield
|
0.09%
|
-0.54%
|
-7.32%
|
-2.89%
|
-1.62%
|
-6.71%
|
Price to Book
|
2.51
x
|
1.99
x
|
4.36
x
|
2.53
x
|
2.03
x
|
2.05
x
|
Nbr of stocks (in thousands)
|
9,937
|
10,587
|
11,626
|
11,830
|
12,348
|
12,757
|
Reference price
2 |
6,080
|
5,630
|
17,400
|
12,100
|
10,800
|
11,840
|
Announcement Date
|
28/03/19
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
33,406
|
40,189
|
40,496
|
44,630
|
63,909
|
92,046
|
EBITDA
1 |
858.5
|
6,340
|
6,788
|
7,087
|
9,699
|
11,985
|
EBIT
1 |
-5,211
|
3,282
|
3,990
|
3,779
|
5,845
|
7,006
|
Operating Margin
|
-15.6%
|
8.17%
|
9.85%
|
8.47%
|
9.15%
|
7.61%
|
Earnings before Tax (EBT)
1 |
-29,527
|
1,902
|
2,057
|
2,056
|
2,465
|
6,787
|
Net income
1 |
-29,763
|
2,506
|
1,574
|
763.9
|
1,781
|
4,055
|
Net margin
|
-89.1%
|
6.23%
|
3.89%
|
1.71%
|
2.79%
|
4.41%
|
EPS
2 |
-2,995
|
246.0
|
147.3
|
64.00
|
146.0
|
251.5
|
Free Cash Flow
1 |
66.51
|
-393.4
|
-15,753
|
-4,163
|
-2,277
|
-11,503
|
FCF margin
|
0.2%
|
-0.98%
|
-38.9%
|
-9.33%
|
-3.56%
|
-12.5%
|
FCF Conversion (EBITDA)
|
7.75%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
21/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
17,099
|
13,830
|
12,961
|
883
|
6,788
|
20,435
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
19.92
x
|
2.181
x
|
1.909
x
|
0.1246
x
|
0.6999
x
|
1.705
x
|
Free Cash Flow
1 |
66.5
|
-393
|
-15,753
|
-4,163
|
-2,277
|
-11,503
|
ROE (net income / shareholders' equity)
|
-76.4%
|
9.28%
|
4.12%
|
1.48%
|
4.02%
|
6.31%
|
ROA (Net income/ Total Assets)
|
-3.96%
|
3.23%
|
3.14%
|
2.2%
|
2.51%
|
2.44%
|
Assets
1 |
7,51,991
|
77,601
|
50,156
|
34,783
|
70,864
|
1,66,223
|
Book Value Per Share
2 |
2,424
|
2,828
|
3,992
|
4,788
|
5,324
|
5,782
|
Cash Flow per Share
2 |
841.0
|
390.0
|
560.0
|
1,146
|
1,273
|
1,339
|
Capex
1 |
3,951
|
3,296
|
6,396
|
8,387
|
6,153
|
10,491
|
Capex / Sales
|
11.83%
|
8.2%
|
15.79%
|
18.79%
|
9.63%
|
11.4%
|
Announcement Date
|
28/03/19
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
21/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -24.75% | 8.38Cr | | +10.11% | 13TCr | | -6.28% | 1.13TCr | | +6.07% | 927.24Cr | | +37.46% | 550.06Cr | | -23.66% | 461.38Cr | | +8.53% | 344.58Cr | | -8.69% | 280.56Cr | | -10.91% | 209.47Cr | | -6.38% | 208.36Cr |
Medical Devices & Implants
|